alogliptin   Click here for help

GtoPdb Ligand ID: 6319

Synonyms: Nesina® | SYR-322 | Vipidia®
Approved drug PDB Ligand
alogliptin is an approved drug (EMA & FDA (2013))
Compound class: Synthetic organic
Comment: Alogliptin is a once-daily, oral dipeptidyl peptidase-4 (DPP-4) inhibitor class anti-diabetic drug.
Click here for help
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: alogliptin

2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 3
Topological polar surface area 97.05
Molecular weight 339.17
XLogP 3.22
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES N#Cc1ccccc1Cn1c(cc(=O)n(c1=O)C)N1CCCC(C1)N
Isomeric SMILES N#Cc1ccccc1Cn1c(cc(=O)n(c1=O)C)N1CCC[C@H](C1)N
InChI InChI=1S/C18H21N5O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3/t15-/m1/s1
No information available.
Summary of Clinical Use Click here for help
Alogliptin is an oral medication for the treatment of type 2 diabetes. Clinical formulations contain alogliptin benzoate (PubChem CID 16088021).
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Alogliptin inhibits dipeptidyl peptidase IV (DPP4). Inhibition of this enzyme increases levels of glucagon like peptide 1. This in turn, inhibits glucagon production from pancreatic α-cells and increases production of insulin from pancreatic β-cells.
External links Click here for help